What is claimed is:

1. An injectable pharmaceutical composition comprising an angiopoietin-2 (Ang-2) inhibitor for use in treating a vascular eye disease or disorder.

2. The composition of claim 1, further comprising a vascular endothelial growth factor (VEGF) antagonist.

3. The composition of claim 2, comprising 40 mg/mL of the VEGF antagonist, and 0.5 mg to 10 mg of the Ang-2 inhibitor.

4. The composition of any one of claims 1 to 3, wherein the eye disease or disorder is selected from the group consisting of diabetic retinopathy, diabetic macular edema, age-related macular degeneration, retinal neovascularization, central retinal vein occlusion, branched retinal vein occlusion, polypoidal choroidal vasculopathy, and choroidal neovascularization.

5. An injectable pharmaceutical composition comprising an Ang-2 inhibitor in combination with a VEGF antagonist for use in treating retinal.

6. The composition of claim 5, wherein the retinal angiogenesis is associated with an eye disease or disorder selected from the group consisting of diabetic retinopathy, diabetic macular edema, age-related macular degeneration, retinal neovascularization, central retinal vein occlusion, branched retinal vein occlusion, polypoidal choroidal vasculopathy, and choroidal neovascularization.

7. An injectable pharmaceutical composition comprising an Ang-2 inhibitor in combination with a VEGF antagonist for use in inhibiting neovascularization.

8. An injectable pharmaceutical composition comprising an Ang-2 inhibitor in combination with a VEGF antagonist for use in inhibiting vascular leak.

9. An injectable pharmaceutical formulation for reducing the number of intravitreal injections administered to a subject with an eye disease,

wherein the formulation is sequentially administering with a first initial dose following by one or more secondary doses of a pharmaceutical composition comprising a therapeutically effective amount of an Ang-2 inhibitor in combination with a VEGF antagonist;

whereby the formulation allows that intravitreal administration of the VEGF antagonist is reduced to once every 9 weeks as compared to a subject who has been administered the VEGF antagonist alone.

10. The formulation of claim 9, wherein the one or more secondary doses comprises 2 – 10 doses of the pharmaceutical composition.

11. The formulation of claim 10, wherein at least 2 secondary doses of the pharmaceutical composition are administered to the subject, and wherein each secondary dose is administered 1 to 4 weeks after the immediately preceding dose.

12. The composition of any one of the preceding claims, wherein the Ang-2 inhibitor is an anti-Ang-2 antibody or antigen binding fragment thereof.

13. The composition of claim 12, wherein the antibody or antigen binding fragment comprises the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) having the amino acid sequence of SEQ ID NO: 1 and the CDRs of a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO: 2.

14. The composition of claim 13, wherein the antibody or antigen binding fragment comprises a heavy chain CDR1 (HCDR1) having the amino acid sequence of SEQ ID NO: 3, a HCDR2 having the amino acid sequence of SEQ ID NO: 4, a HCDR3 having the amino acid sequence of SEQ ID NO: 5, a light chain CDR1 (LCDR1) having the amino acid sequence of SEQ ID NO: 6, a LCDR2 having the amino acid sequence of SEQ ID NO: 7, and a LCDR3 having the amino acid sequence of SEQ ID NO: 8.

15. The composition of claim 14, wherein the antibody or antigen binding fragment thereof comprises a HCVR having the amino acid sequence of SEQ ID NO: 1 and a LCVR having the amino acid sequence of SEQ ID NO: 2.

16. The composition of any one of the preceding claims, wherein the VEGF antagonist comprises a VEGF receptor-based chimeric molecule (VEGF Trap).

17. The composition of claim 16, wherein the VEGF Trap comprises one or more immunoglobulin (Ig)-like domains of VEGFR1, one or more Ig-like domains of VEGFR2, and a multimerizing domain.

18. The composition of claim 17, wherein the VEGF Trap comprises Ig-like domain 2 of VEGFR1, Ig-like domain 3 of VEGFR2, and a multimerizing domain.

19. The composition of claim 16, wherein the VEGF Trap is aflibercept.

20. The composition of any one of the preceding claims, wherein the VEGF antagonist consists of a dimer of two polypeptides consisting of amino acids 27-457 of SEQ ID NO: 11.

21. A stable liquid formulation comprising: (i) a vascular endothelial growth factor (VEGF) antagonist; (ii) an antibody that binds specifically to human angiopoietin-2 (hAng-2); (iii) a buffer at pH of 6.2 ± 0.3; (iv) a non-ionic detergent; (v) a tonicity agent; and (vi) a stabilizer; wherein the VEGF antagonist consists of a dimer of two polypeptides consisting of amino acids 27-457 of SEQ ID NO: 11.

22. The formulation of claim 21, wherein the antibody comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) wherein HCDR1 has SEQ ID NO: 3, HCDR2 has SEQ ID NO: 4, HCDR3 has SEQ ID NO: 5, and three light chain CDRs (LCDR1, LCDR2 and LCDR3), wherein LCDR1 has SEQ ID NO: 6, LCDR2 has SEQ ID NO: 7, and LCDR3 has SEQ ID NO: 8.

23. The formulation of any one of claims 21 and 22, wherein the antibody comprises a heavy chain variable region (HCVR) of SEQ ID NO: 1 and a light chain variable region (LCVR) of SEQ ID NO: 2.

24. The formulation of claim 23, wherein the VEGF antagonist concentration is about 40 mg/mL ± 1.5 mg/mL.

25. The formulation of claim 24, comprising about 10 – 120 mg/mL of the antibody.

26. The formulation of claim 25, comprising the antibody at a concentration selected from the group consisting of 10 mg/mL, 20 mg/mL, 60 mg/mL, and 120 mg/mL.

27. The formulation of claim 21, comprising about 5 – 100 mg/mL of the VEGF antagonist; about 10 – 120 mg/mL of the anti-Ang-2 antibody; about 5 – 50 mM sodium phosphate, pH about 6.2; about 0.01 – 0.1% (w/v) polysorbate; about 10 – 50 mM sodium chloride; and about 1 – 20% (w/v) sucrose.

28. The formulation of claim 27, comprising the antibody at a concentration selected from the group consisting of 10 mg/ml, 20 mg/ml, 60 mg/ml, and 120 mg/ml.

29. The formulation of claim 26, wherein (a) the buffer is sodium phosphate;

(b) the sodium phosphate concentration is 10 mM ± 1.5 mM;

(c) the non-ionic detergent is polysorbate 20;

(d) the polysorbate 20 concentration is 0.03% w/v ± 0.0045%;

(e) the tonicity agent is sodium chloride;

(f) the sodium chloride concentration is 40 mM ± 6.0 mM; and

(g) the stabilizer is sucrose is present in a concentration of 5% ± 0.75%.

30. The formulation of claim 21, wherein the VEGF antagonist concentration is 40 mg/mL ± 6.0 mg/mL, the antibody concentration is 10 mg/mL ± 1.5 mg/mL, the buffer is 10mM ± 1.5mM sodium phosphate, pH 6.2 ± 0.3, the non-ionic detergent is 0.03% w/v ± 0.0045% polysorbate 20, the tonicity agent is 40mM sodium chloride, and the stabilizer is 5% w/v ± 1.5% sucrose.

31. The formulation of claim 21, wherein the VEGF antagonist concentration is 40 mg/mL ± 6.0 mg/mL, the antibody concentration is 20 mg/mL ± 3.0 mg/mL, the buffer is 10mM ± 1.5mM sodium phosphate, pH 6.2 ± 0.3, the non-ionic detergent is 0.03% w/v ± 0.0045%

polysorbate 20, the tonicity agent is 40mM sodium chloride, and the stabilizer is 5% w/v ± 1.5% sucrose.

32. The formulation of claim 21, wherein the VEGF antagonist concentration is 40 mg/mL ± 6.0 mg/mL, the antibody concentration is 60 mg/mL ± 9.0 mg/mL, the buffer is 10mM ± 1.5mM sodium phosphate, pH 6.2 ± 0.3, the non-ionic detergent is 0.03% w/v ± 0.0045% polysorbate 20, the tonicity agent is 40mM sodium chloride, and the stabilizer is 5% w/v ± 1.5% sucrose.

33. The formulation of claim 21, wherein the VEGF antagonist concentration is 40 mg/mL ± 6.0 mg/mL, the antibody concentration is 120 mg/mL ± 18.0 mg/mL, the buffer is 10mM ± 1.5mM sodium phosphate, pH 6.2 ± 0.3, the non-ionic detergent is 0.03% w/v ± 0.0045% polysorbate 20, the tonicity agent is 40mM sodium chloride, and the stabilizer is 5% w/v ± 1.5% sucrose.

34. The formulation of any of claims 21-28 and 30-33 for use in treating or ameliorating a vascular eye disease or disorder in a subject in need thereof.